牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. officer and director, Gibson Christopher, is set to sell 25,000 Class A shares on 03/06/2024, as per the latest SEC filing. The shares, valued at an aggregate market value of $288,817.01, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 163,954 shares were sold for gross proceeds of approximately $1.42 million.
Recursion Pharmaceuticals, Inc. officer and director, Gibson Christopher, is set to sell 25,000 Class A shares on 03/06/2024, as per the latest SEC filing. The shares, valued at an aggregate market value of $288,817.01, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 163,954 shares were sold for gross proceeds of approximately $1.42 million.
根據美國證券交易委員會的最新文件，Recursion Pharmicals, Inc.高管兼董事吉布森·克里斯托弗定於2024年6月3日出售25,000股A類股票。這些股票的總市值爲288,817.01美元，最初是作爲發行人薪酬的一部分於2016年1月9日作爲創始人股票收購的。此次計劃出售是在過去三個月進行的一系列交易之後進行的，共出售了163,954股股票，總收益約爲142萬美元。
根據美國證券交易委員會的最新文件，Recursion Pharmicals, Inc.高管兼董事吉布森·克里斯托弗定於2024年6月3日出售25,000股A類股票。這些股票的總市值爲288,817.01美元，最初是作爲發行人薪酬的一部分於2016年1月9日作爲創始人股票收購的。此次計劃出售是在過去三個月進行的一系列交易之後進行的，共出售了163,954股股票，總收益約爲142萬美元。
有用
沒用